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Abstract
The immunosuppressive drug cyclosporin A (CsA) has inhibitory effects on the replication of several viruses. The antiviral
effects are through targeting the interaction between viral proteins and host factor cyclophilin A (CypA). CypA has been
identified to interact with influenza A virus M1 protein and impair the early stage of the viral life cycle. In order to identify
the effect of CsA on influenza virus replication, a CypA-depleted 293T cell line, which was named as 293T/CypA2, was
constructed. The cytopathic effect (CPE) assay and the growth curve results indicated that CsA specifically suppressed the
influenza A virus replication in a dose-dependent manner. CsA treatment had no effect on the viral genome replication and
transcription but selectively suppressed the viral proteins expression. Further studies indicated that CsA could impair the
nuclear export of viral mRNA in the absence of CypA. In addition, the antiviral activity of CsA was independent of calcineurin
signaling. Finally, CsA could enhance the binding between CypA and M1. The above results suggested that CsA inhibited
the replication of influenza A virus through CypA-dependent and -independent pathways.
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Introduction
Many of interactions between influenza viral components and
host factors have now been identified. Emerging data indicate that
their identification and characterization will provide new insights
into the mechanisms by which viruses complete their life cycle.
Furthermore, such knowledge would illuminate potentially useful
targets for therapeutic intervention. For example, human immu-
nodeficiency virus type 1 (HIV-1) has been tested or treated with
the antiviral drugs targeting host cell factors involved in viral
replication [1]. However, this goal would generally take several
decades to achieve with conventional genetic screening methods
and mammalian cell cultures.
The well-known immunosuppressive drug cyclosporin A (CsA)
is a cyclic 11-amino-acid peptide produced by the fungus
Tolypocladium inflatum. It was reported that CsA had antiviral
activity on the replication of several viruses through targeting the
interaction between the viral proteins and host factor CypA, which
is the major intracellular receptor for CsA [2,3,4,5,6]. For
example, CsA can disrupt the interaction of Gag-CypA in vitro,
block CypA incorporation into virions, and inhibit viral replication
[4,5]. CsA inhibits hepatitis C virus replication mainly through
CypA [3,7,8,9]. In addition, it has been reported if administered
with a dose of influenza virus lethal for normal mice, CsA-treated
mice greatly survived compared to control, suggesting CsA may
inhibit the influenza virus replication [10]. In the previous study,
CypA has been identified to interact with influenza A virus M1
protein and accelerate the degradation of M1 protein [11,12].
Therefore, it is of interest to investigate the effect of CsA on
influenza A virus replication at the cell level and to determine in
more detail whether the regulation of influenza viral replication by
CsA involves the CypA interaction with M1.
In the present study, we investigated the effect of CsA on the
intracellular replication of influenza A virus, using a control cell
line which was named as 293T/CypA+ as control and a CypA
depleted 293T cell line which was named as 293T/CypA2. The
results indicated that CsA inhibited the replication of influenza A
virus at the post transcription level. The molecular mechanism of
CsA was not only through CypA-dependent pathway but also
CypA-independent pathway.
Results
CsA inhibited the replication of influenza A virus in
a dose-dependent manner
The effect of CsA on influenza A virus replication was
investigated at the cell level. A dose response curve with various
concentrations of CsA (control, 2.5–10 mg/ml) revealed that, at
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e3727736 h p.i., less cytopathic effect (CPE) observed in the higher
treated concentration of CsA and more CPE in the lower treated
concentration of CsA in MDCK cells infected with influenza virus
of H1N1 subtype (A/WSN/33) (Figure 1A). In addition, CsA had
similar effects on the influenza virus of H9N2 subtype (A/
Chicken/Liaoning/1/00) infected MDCK cells (data not shown).
The present data showed that CsA effectively inhibited the
influenza A virus when CsA was added to the cell culture following
virus adsorption. At 16 h p.i., the titer of viruses in the supernatant
was analyzed by plaque assay. As shown in Figure 1B, the titer of
viruses in the supernatant was decreased with the increasing
concentrations of CsA. No significant cytotoxic effects were
observed in uninfected cells exposed to 2.5–10 mg/ml of CsA.
Since 10 mg/ml of CsA caused marked morphological alterations
and decreased cell viability (data not shown), all subsequent
experiments were performed with 5 mg/ml of CsA.
The multiplication assay was performed to determine the
antiviral effect of CsA. MDCK cells were infected with influenza
A/WSN/33 (MOI=0.01) for 1 h. After being washed with
phosphate buffered saline (PBS) three times, the cells were cultured
with fresh medium supplemented with or without 5 mg/ml of CsA.
At various time points post infection, viral titers in the super-
natants were detected by plaque assay. As shown in Figure 1C, the
growth curve indicated that CsA inhibited the influenza virus
replication in MDCK cells.
CypA inhibited the replication of influenza virus in CypA
rescued cells
In order to study the mechanism of CsA in the influenza A virus
replication, the CypA-depleted stable cell line and the luciferase-
depleted cell line as control were established using the pSUPER
RNAi System [12]. Several clonal populations of GFP expressing
cells were obtained and measured for CypA depletion. The
amount of CypA in cell was characterized. There was no
detectable CypA in 293T/CypA2 cell line compared with that
in 293T/CypA+ cell line. The amount of b-actin as control was
similar in both cell lines as shown in Figure 2A. In addition, except
for the expression level of CypA, no significant differences in cell
morphology and cell cycle were observed between the two cell
lines. When CypA was rescued through transfecting with pCMV-
Myc-CypA in 293T/CypA2 cell line, the intracellular expression
level of M1 in CypA-transfected cells was lower than the vector
control (Figure 2B). Plaque assay showed that at 16 h p.i., the
number of virus particles that were released from CypA-
transfected 293T/CypA2 cells resulted in nearly three-fold
reduction of the virus titer levels seen in the cells transfected with
a pCMV-Myc empty plasmid (Figure 2C).
CsA inhibited the viral replication through cyclophilin A-
dependent and -independent pathways
To determine whether CsA’s inhibition of viral replication was
related to the host factor CypA, both 293T/CypA+ and 293T/
CypA2 cell lines were treated with CsA (5 mg/ml) immediately
after influenza A/WSN/33 infection (MOI=1), and a time-course
experiment for antiviral activity of CsA was performed at 4 h, 6 h
and 8 h p.i. by Western blot analysis. As shown in Figure 3A, CsA
treatment significantly decreased the expression of the M1 protein
in both cell lines at 6 h p.i. and 8 h p.i. compared with the control
groups. Similar results were obtained in the NS1 protein. While
CsA had different effects on the expression of NP protein in two
cell lines. In 293T/CypA+ cell line, CsA decreased the expression
of NP protein. However, the expression level of NP was little less in
the presence or absence of CsA in 293T/CypA2 cell line. These
Figure 1. CsA inhibited the influenza virus replication in MDCK
cell line. A: Cytopathic effect assay of CsA on the influenza virus
replication. Monolayers of MDCK cells on 96-well microwell plates were
infected with influenza A/WSN/33 (MOI=0.1). Infected cells were
treated in duplicate with different concentrations of CsA (Control,
2.5 mg/ml, 5 mg/ml, 10 mg/ml) in DMEM with 2 mg/ml TPCK-treated
trypsin, and the preparations were incubated at 37uC for another 36 h,
after which the monolayers were stained with crystal violet (0.1% in
20% ethanol) and examined for cytopathic effect (CPE). Data are
presented as the mean plusminus standard deviation (6 SD) from three
independent experiments. B: Plaque assay of the titer of viruses in the
supernatant with different concentrations of CsA (0–10 mg/ml). Infected
cells were treated in duplicate with different concentrations of CsA
(0 mg/ml, 2.5 mg/ml, 5 mg/ml, 10 mg/ml) in DMEM with 2 mg/ml trypsin,
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the influenza virus replication. One was CypA-dependent
pathway. The other was CypA-independent pathway. In addition,
we analyzed the viral titers in the supernatants at 8 h p.i. in detail
(Figure 3B) when the first viral life cycle was over. In 293T/
CypA+ cell line, the viral titer was 158 PFU/ml in the presence of
DMSO, while the virus released from the cells in the presence of
CsA was too little to be detected at 8 h p.i. In 293T/CypA2 cell
line, the viral titer was 541 PFU/ml with the treatment of DMSO
and it was more than 3 fold of that in 293T/CypA+ cell line. The
virus could also be detected in the presence of CsA and the viral
titer was 75 PFU/ml. The virus released earlier in 293T/CypA2
than in 293T/CypA+ cell line. The results further proved our
previous results that CypA was an inhibition factor for influenza
virus [11,12]. Furthermore, CsA inhibited the viral replication
through CypA-dependent and -independent pathways.
CsA inhibited the influenza virus replication through
targeting a post-transcriptional level
To understand whether the effect of CsA on the M1 protein
expression was related with the transcription or replication phase
of the virus life cycle, mRNA, vRNA, cRNA for M1 were
measured in control and CsA-treated cells by real-time PCR using
specific primers for viral mRNA, vRNA, cRNA at 2 h, 4 h and
8 h p.i. Real-time PCR assays indicated that the M1 mRNA levels
were similar in control and CsA-treated cells (Figure 4A, B).
Furthermore, there were no significant differences at the levels of
M1 vRNA, cRNA in control or CsA-treated cells (Figure 4C to F).
Combining with the results that the expression of M1 protein and
virus production were significantly decreased with the treatment of
CsA, the inhibitory effect of CsA on the M1 protein expression
occurred at a post-transcriptional level.
CsA impaired the nuclear export of viral mRNA in the
absence of CypA
As was shown, CsA did not affect the transcription and genome
replication of influenza virus. To determine if CsA has an effect on
viral mRNA nuclear export, we compared the nuclear and
cytoplasmic abundance of M1 and NP mRNA upon influenza
virus infection at 4 h post-infection in 293T/CypA2 cell line, in
which the effect of CypA could be eliminated. First of all, the
nuclear and cytoplasmic fractions were isolated and analyzed by
Western blotting for lamin B1 and a-tubulin (Figure 5A). The
results showed that the nuclear/cytoplasmic fractions were isolated
well. With the help of quantitative real time PCR, the mRNA of
M1 and NP were detected. These results indicated that the ratio of
nuclear/cytoplasm M1 mRNA was lower in CsA treated 293T/
CypA2 cell line than that in DMSO treated cells (Figure 5B). In
addition, we obtained similar results for the pattern of NP mRNA
(Figure 5C). These results suggested that CsA could impair the
nuclear export of viral mRNA through CypA-independent
pathway.
The effect of CsA on influenza virus replication was
independent of calcineurin signaling
In mammals, the CsA-CypA complex binds to and inhibits
calcium-dependent phosphatase calcineurin [13,14]. MeIle
4-CsA
is a CsA analogue that binds CypA as tightly as the CsA-CypA
complex but does not form a complex with calcineurin. So MeIle
4-
CsA is a nonimmunosuppressive CsA analogue [4,15]. To identify
the mechanism of CsA on the influenza virus replication, 293T/
CypA+ and 293T/CypA2 cell lines were infected with influenza
A/WSN/33 (MOI=0.1) in the presence or absence of CsA or
Melle
4-CsA, respectively. At 8 h p.i., M1 protein levels in the cell
lysates were detected. The results indicated that there was no
difference between Melle
4-CsA and CsA on the expression of M1
protein (Figure 6A). In addition, the viral titer in the supernatant
and the preparations were incubated at 37uC for another 16 h, after
which the titer of viruses in the supernatant was analyzed by plaque
assay. Data are means 6 SD of three separate experiments. C: The
growth curves of influenza virus in MDCK cell line in the absence or
presence of CsA (5 mg/ml).The cells were infected with influenza A/
WSN/33 (MOI=0.01) for 1 h. After being washed with PBS 3 times, the
cells were cultured with fresh medium supplemented without or with
CsA (5 mg/ml). At various times post-infection, viral titers in the
supernatants were determined by plaque assay. Data are means 6 SD
of three separate experiments.
doi:10.1371/journal.pone.0037277.g001
Figure 2. CypA inhibits the replication of influenza virus in CypA rescued cells. A: Western blot assay of the amount of CypA in both 293T/
CypA+ and 293T/CypA2 cell lines. B: Re-expression of CypA in 293T/CypA2 cell line. 293T/CypA2 cells were transfected with plasmids (4 mg)
encoding Myc-tagged WT CypA or pCMV-Myc as control. At 36 h p.t., transfected cells were infected with WSN virus (MOI=0.1). At 16 h p. i., total cell
lysates were detected by Western blot using anti-M1, anti-Myc and anti-b-actin. The protein levels of M1 were quantified. Data are presented as 6 SD
from three independent experiments. Significant differences (P,0.01, t-test) are indicated by two asterisks. C: Re-expression of CypA in 293T/CypA2
cell line inhibited influenza virus replication. The media were collected and assayed for virus titers by plaque assay. The data represent the means of
three independent experiments.
doi:10.1371/journal.pone.0037277.g002
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4-CsA
treated cells (Figure 6B). Thus, the inhibition of the viral
replication by CsA was independent of calcineurin signaling.
CsA enhanced the binding between CypA and M1
In the previous study, we found that CypA interacted with M1
and affected the early stage of influenza virus replication. As is
shown, CypA, in particular, is the major intracellular receptor for
CsA [2]. In order to identify the effect of CsA on the interaction
between CypA and M1, GST pull-down assay was performed to
demonstrate that the binding capacity between CypA and M1 was
increased in a dose-dependent manner with treatment of CsA
(Figure 7, lanes 3–5). As a control, we chose another member of
cyclophilin family, Cypclophilin B (CypB). CypB could interact
with M1 in vitro, the interaction between M1 and CypB was not
affected by CsA treatment (Figure 7, lanes 7–9). In our previous
study, over-expression or knock-out of CypB has no effect on the
influenza virus replication [11]. These results suggested that CsA
might be involved in influenza A virus replication partially through
regulating the interaction between CypA and M1.
Discussion
CsA has antiviral effects on several viruses in different manners
including herpes simplex virus (HSV), vaccinia virus (VV), BK
polyomavirus (BKV), HIV-1 and hepatitis C virus (HCV)
[3,4,7,8,16,17,18,19,20,21]. Two well-studied antiviral effects of
CsA was related to HCV and HIV [3,4,5,6,19,20,21,22,23]. As for
HCV, CypB was firstly found to associate with NS5B and to
stimulate its RNA binding activity and CsA primarily targeted
NS5B by way of CypB to inhibit the viral replication [22,24].
However, further studies indicated that CypA is crucial for HCV
replication. CsA could inhibit the interaction between CypA and
the NS5A protein of HCV and CsA also targeted the NS2 protein
through CypA to inhibit the replication of HCV [3,7,8,9]. Thus,
CsA might combine with the both cyclophilin family proteins to
regulate the replication of HCV. Upon HIV-1 infection, CsA
disrupted the interaction between CypA and capsid (CA) and then
inhibited the viral replication [4]. In addition, CsA could block the
incorporation of HIV-1 envelope glycoprotein into virions [25]. In
the present study, CsA was determined to inhibit the influenza A
virus replication at the cell level. It was found that CsA enhanced
the binding between CypA and M1 while not between CypB and
M1. CsA treatment might increase the affinity of CypA to M1 to
form ternary complex of CsA-CypA and M1. The formation of
this complex might hinder the translocation of M1 protein during
the replication of the virus. In addition, GST pull-down assay
indicated that CypB interacted with M1 protein, while CsA had
no effect on the binding ability between them. These results were
in accordance with the previous study that over-expression or
knock-down of CypB could not affect the influenza virus
replication [11].
It was noticed that CsA treatment reduced the M1 protein
expression level (Figure 3) but not the mRNA, vRNA and cRNA
levels of M1 gene (Figure 4), suggesting that CsA perhaps inhibited
influenza virus replication by targeting at a post-transcriptional
level. The inhibitory abilities were different in 293T/CypA+ cell
line compared with 293T/CypA2 cell line (Figure 3). CsA
inhibited the M1 protein level more effectively in 293T/CypA+
cell line than in 293T/CypA2 cell line, which suggested CsA
mainly targeted CypA protein for inhibiting the viral replication.
However, there was still inhibitory effect of CsA on the influenza
virus replication in 293T/CypA2 cell line. Overall, the present
evidence indicated that the effect of CsA on influenza A virus
replication was not only through CypA2 dependent pathway.
There was a CypA2 independent pathway to inhibit the
replication of influenza A virus by targeting the post-transcription
of influenza virus life cycle. The nuclear and cytoplasmic mRNA
quantification of influenza viral mRNA indicated that CsA could
impair the nuclear export of viral mRNA in the absence of CypA
(Figure 5). As was reported, nuclear export of influenza A virus
mRNAs required ongoing RNA polymerase II activity. Influenza
A virus replication requires RNAP II activity not just to provide
capped mRNA substrates but also to facilitate nuclear export of
selected viral mRNAs of HA, M1 and NS1 genes while not NP
and NEP [26]. CsA could inhibit the activity of RNA polymerase
II while not RNA polymerase III or RNA polymerase I [27]. We
deduced that the CypA-independent pathway of CsA was that
CsA might inhibit the influenza virus replication through
impairing the nuclear export of viral mRNA by inhibiting the
activity of RNA polymerase II.
All currently approved anti-inuenza drugs target essential viral
functions and/or structures. The major drawback of this approach
is that the virus will eventually adapt to the drug selective pressure
[28]. To manipulate the interaction between host cell factor and
Figure 3. CsA selectively inhibited the viral proteins levels in
both 293T/CypA+ and 293T/CypA2 cells. Both cell lines were
infected with inuenza A/WSN/33 at MOI 1. After being washed with PBS,
the cells were cultured with fresh medium supplemented without or
with CsA (5 mg/ml). At 4 h p.i., 6 h p.i. and 8 h p.i., the cell lysates were
collected to detect the M1, NP and NS1 proteins. b-actin as an internal
control was also detected by Western blot analysis (A). The relative viral
protein levels of M1, NP and NS1 in both 293T/CypA+ and 293T/CypA2
cells were calculated by quantifying the results shown in panel (A). The
viral titers were detected at 8 h p.i. in two cell lines (B). Data are means
6 SD of three separate experiments.
doi:10.1371/journal.pone.0037277.g003
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way to develop the antiviral drug. In the present study, CsA
inhibited the influenza virus replication partially through regulat-
ing functional CypA. In addition, the immunosuppression activity
of CsA was not needed for its anti-influenza virus activity. So we
can develop the derivatives of CsA which have low toxicity and
high activity as the anti-influenza virus drug. In addition, CsA
plays critical roles in the replications of several viruses through its
high affinity with the cyclophilin family members. So CsA and its
derivatives could be used as the promising strategies to explore the
regulation mechanism of the virus replication.
Figure 4. CsA inhibited the influenza virus replication at post-transcriptional level. 293T/CypA2 and 293T/CypA+ cell lines were infected
with influenza A/WSN/33 (MOI=1) in the absence or presence of CsA (5 mg/ml). RNA of the infected cells at 2 h, 4 h and 8 h p.i. was extracted and
assayed using the specific primers for influenza RNA by RT-PCR. The M1 mRNA level (A and B), vRNA level (C and D) and cRNA level (E and F) of the
both cell lines were quantified by real-time PCR analysis using the specific primer for M1. The mRNA of GAPDH was kept as an internal control. Data
are means 6 SD of three separate experiments.
doi:10.1371/journal.pone.0037277.g004
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Ethics statement
The use of all laboratory animals and animal subjects in our
study was approved by the Beijing Association for Science and
Technology, with approval ID SYXK (Beijing) 2007–0023, and all
procedures were carried out in accordance with the Beijing
Laboratory Animal Welfare and Ethical Guidelines of the Beijing
Administration Committee of Laboratory Animals. Rabbit anti-
CypA polyclonal antibody was prepared by Beijing Cowin Biotech
Co., Ltd, Beijing, China, with approval from the Beijing
Association for Science and Technology, ID SYXK (Beijing)
2007–0023. The authors supplied the purified His-CypA protein.
The cell line HEK293T was generously provided by Jilong Chen,
Institute of Microbiology, Chinese Academy of Sciences, who is
also one of the authors of this manuscript.
Cell lines, viruses and antibodies
Madin-Darby Canine Kidney (MDCK) cells (ATCC CCL-34),
human embryonic kidney 293T cells [29] were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS;
GIBCO). Influenza A virus strain A/WSN/33 (H1N1) and A/
Chicken/Liaoning/1/00 (H9N2) were used in these experiments,
and they were propagated in MDCK cells. For rabbit anti-CypA
polyclonal antibody, purified hexahistidine-tagged CypA (His-
CypA) was provided to company (Beijing Cowin Biotech Co., Ltd,
Beijing, China) for immunization. Mouse anti-M1 monoclonal
antibody was prepared as described previously [30]. Mouse anti-
NS1 monoclonal antibody (sc-130568) and anti-b-actin (sc-1616-
R) were purchased from Santa Cruz Biotechnology.
Construction of plasmids
The CypA and cyclophilin B (CypB) genes were obtained by
PCR from the human kidney cDNA library (Clontech), and
subcloned into the bacterial expression vector pGEX-6p-1,
respectively. The full-length M1 gene of A/WSN/33 was
subcloned into the bacterial expression vector pET30a (+)a s
described previously [11]. The full-length NP and M1 genes of
PR8 were subcloned into the plasmid pCMV-Tag2, respectively.
Figure 5. CsA impaired the nuclear export of influenza virus
mRNA in the absence of CypA. The 293T/CypA2 cell line was
infected with A/WSN/33 (MOI=0.1) in the presence or the absence of
CsA. At 4 h post-infection, Nuclear (N) and cytoplasmic (C) components
were isolated from the infected 293T/CypA2 cell line. One tenth of the
components were used for Western blot by anti-alpha-tubulin and anti-
lamin B1 (A). The rest of the components were used for the RNA
extraction and real time PCR. M1 (B)and NP (C) mRNA levels were
quantified by real-time RT-PCR using gene-specific primers. Data are
means 6 SD of three separate experiments.
doi:10.1371/journal.pone.0037277.g005
Figure 6. The effect of CsA on influenza virus replication in
both 293T/CypA+ and 293T/CypA2 cells was independent of
calcineurin signaling. Both cell lines were infected with inuenza A/
WSN/33 at MOI 1. After being washed with PBS, the cells were cultured
with fresh medium supplemented without or with CsA, Melle
4-CsA
(5 mg/ml). At 8 h p.i., the cell lysates were collected to detect the M1
protein. b-actin as an internal control was also detected by Western blot
analysis (A). The viral titers in the supernatants were determined by
plaque assay (B). Data are means 6 SD of three separate experiments.
doi:10.1371/journal.pone.0037277.g006
Figure 7. CsA enhanced the binding between CypA and M1.
GST pull-down assays between GST-CypA and M1, GST-CypB and M1
were performed in the absence (lane 3, lane 7) or presence (lanes 4, 5, 8,
9) of CsA. The concentrations of CsA in lanes 4, 5, 8, 9 are 2.5, 5, 2.5,
5 mg/ml, respectively. Coomasie brilliant blue (CBB) staining patterns for
the pulled-down proteins are shown in the bottom panel.
doi:10.1371/journal.pone.0037277.g007
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37277CPE assay
To study the effect of CsA (Sigma) on the cytopathic effect
(CPE) in the influenza virus infected MDCK cells, 96-well
microtiter plates were seeded with 10
4 MDCK cells/0.1 ml per
well. Monolayers were allowed to develop for 18 h in growth
medium containing 10% fetal bovine serum at 37uC, resulting in
75% or greater confluency. The wells were washed with PBS and
inoculated with 100 ml of influenza virus (A/WSN/33 and A/
Chicken/Liaoning/1/00) diluted in DMEM with 2 mg/ml
TPCK-treated trypsin (MOI=0.1). After the virus was absorbed
at 37uC for 1 h, the wells were washed with PBS, and then CsA
was added at 2.5 mg/ml, 5 mg/ml, 10 mg/ml in DMEM with
2 mg/ml TPCK-treated trypsin, and then the preparations were
incubated at 37uC for 36 h. The monolayers were stained with
crystal violet (0.1% in 20% ethanol) and the CPE was examined.
Growth curve
MDCK cells were inoculated with influenza virus (A/WSN/33)
(MOI=0.01) to determine the effect of CsA on the virus
replication. Following adsorption for 1 h at 37uC, the virus-
containing medium was removed and fresh medium was added to
the cells in the absence or presence of CsA (5 mg/ml). At time
points 0, 12, 24, 36, 48 h, the supernatants were collected and
determined by the plaque titer on MDCK cells.
RNA extraction and cDNA synthesis
Total RNA from transfected or infected cells were harvested by
Trizol reagent (Invitrogen). Genomic DNA was digested by DNase
Turbo (Ambion) for 30 min prior to reverse-transcription reac-
tions. 1.5 mg of total RNA was reverse transcribed by SuperScript
II reverse transcriptase (Invitrogen) and 10 pmol of vRNA specific
primer (59-AGCAAAGCAGG-39;5 9-AGCAAAAGCAGG-39)
[31], 10 pmol of cRNA specific primer (59-AGTAGAAA-
CAAGG-39) or 50 pmol of oligo-dT primer was used in each
reaction. Negative controls (amplifications in the absence of RNA
or primers) were included in parallel to ascertain absence of
contamination by template nucleic acids and the efficiency in RT
inactivation. The synthesized cDNA was subjected to real-time
PCR analysis.
Real-time PCR analysis
Real-time PCR was performed with the SYBR premix Ex taq
(TaKaRa, Japan) on a corbett 6200 real time detection system
(Corbett, Australia). The real-time PCR amplifications were
carried out in triplicates in a total volume of 20 ml containing
10 ml SYBR green 26premix, cDNA, primers (final concentration
of 0.2 mM). The primers are as follows: the forward primer (59-
CCTGTCACCTCTGACTAAGGGG-39) and the reverse primer
(59-TAGGGCATTTTGGACAAATCGT-39), corresponding to
nucleotide position between 153 and 252 of A/WSN/33 M1
gene [32]; The GAPDH mRNA served as an internal control
using PCR primers: the forward primer of GAPDH (59-
GGTGGTCTCCTCTGACTTCAACA-39) and the reverse prim-
er of GAPDH (59-GTTGCTGTAGCCAAATTCGTTGT-39), as
described in [33]. The PCR program was 95uC for 30 s followed
by 40 cycles of 94uC for 5 s, 60uC for 30 s and dissociation curve
analysis of amplification products was performed at the end of
each PCR reaction to confirm that only one PCR product was
amplified and detected. Each sample was run in triplicate along
with the internal control gene. Dissociation curve analysis was
performed after each assay to ensure specific target detection. Data
analysis of real-time PCR was performed with Rotor Gene 6000
series Software (Corbett, Australia).
Nuclear and cytoplasmic mRNA quantification by real-
time PCR
Nuclear and cytoplasmic RNA was fractionated from cells as
described in [12,34]. Briefly, the cells were lysed in RSB (10 mM
Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl2) containing 0.5%
Nonidet P-40, 10% glycerol, and 100 units/ml rRNasin
(Promega). Nuclei were further washed with 1% Tween-40 and
0.5% sodium deoxycholate, and RNA from both cytoplasmic and
nuclear fractions was purified using Trizol (Invitrogen). The
purified RNA samples were treated with DNase I (TaKaRa) for
30 min at 37uC. One microgram of total RNA was used for cDNA
synthesis with the oligo(dT)18 primer, followed by real-time RT-
PCR quantification. Negative controls (amplifications in the
absence of RNA or primers) were included in parallel to ascertain
absence of contamination by template nucleic acids and the
efficiency in RT inactivation. The standard plasmids for M1 and
NP gene were constructed as reference standard used in absolute
quantification assay. The resulting M1 and NP mRNA levels were
detected by real-time quantitative PCR.
Plaque assay
Plaque assays were performed as previously described [11].
MDCK cell monolayers (1.5610
6 cells at a confluency of 100% in
35 mm dishes) were washed with PBS
+ (PBS supplemented with
0.5 mM MgCl2 and 1 mM CaCl2) and infected with different
dilutions of virus for 1 h at 37uC. The virus inoculum was
removed by washing with PBS. Cell monolayers were then
overlaid with agar overlay medium (DMEM supplemented with
0.6% low-melting-point agarose and 2 mg/ml TPCK-treated
trypsin) and incubated at 37uC. Visible plaques were counted at
2 d p.i. and the virus titers were determined. All data was
expressed as the mean of three independent experiments.
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